Read the headlines these days and you’d think the health insurance companies are going broke. It’s true most insurers offering Obamacare are losing money on it. UnitedHealth Group, the nation’s largest…
Are cancer drugs worth the cost? That’s the question a controversial Boston-based non-profit, the Institute for Clinical and Economic Review (ICER), convened about last week in St. Louis to discuss. The group,…
Having just hosted the latest of a decades-long string of presidential debates, St. Louis is rightfully proud of serving as a setting for vital national conversations. On Oct. 20, the…
Ahead of an ICER meeting to review evidence and vote on cost-effectiveness ratings for non-small cell lung cancer treatments, a group of oncologists is airing “serious concerns” about the organization’s…
The Institute for Clinical and Economic Review, a nonprofit organization that assesses evidence on the value of medical treatments and tests, held its inaugural Midwest Comparative Effectiveness Public Advisory Council…
Concern over rising health care costs has led to some proposals that could be dangerous for cancer patients like myself. I’ve lived with multiple myeloma, a cancer of cells in…
Recently, the Institute for Clinical and Economic Review (ICER), released a scoping document outlining its intentions to evaluate the cost effectiveness of drugs used to treat the autoimmune disease Rheumatoid…
An increasingly influential nonprofit is undercutting medical innovation and building barriers to access between patients and their medicines – all under the guise of a cost-cutting scheme that puts the…
Drug companies and insurance companies aren’t getting along lately, and patients as well as their doctors are caught in the crossfire. Certain drug therapies have changed the way we fight…
On August 9, 2016, The Institute for Clinical and Economic Review (ICER), released a report addressing “myths” about its organization. The document aimed to clarify “ICER’s history, mission, and methods…